Toripalimab NDA Under Review in Hong Kong for Nasopharyngeal Carcinoma #oncology #hncsm #medtwitter onclive.com/view/toripalim…

Vebreltinib Receives NMPA Approval in China for MET Fusion+ Glioma #hncsm #oncology onclive.com/view/vebreltin…

FDA Grants Fast Track Designation to CTX-009 Plus Paclitaxel for Pretreated Biliary Tract Cancer U.S. FDA #oncology onclive.com/view/fda-grant…

Retrospective Data Show Association Between HER2 Expression and Survival Outcomes in mCRC USC Norris Comprehensive Cancer Center #OncClub #crcsm
onclive.com/view/retrospec…

Pembrolizumab Plus Chemo Could Represent New SOC in Advanced/Recurrent Endometrial Cancer Ramez Eskander @UCSD_OBGYN @sgo_org @SGOMtg #gyncsm
onclive.com/view/pembroliz…

Health Canada has approved pembrolizumab plus chemotherapy for first-line, locally advanced, unresectable, or metastatic, HER2-negative gastric/GEJ cancer. #oncology onclive.com/view/first-lin…

The FDA indicated that patients and participants in clinical trials receiving CAR T-cell therapy should be monitored life-long for secondary malignancies. #mmsm #lymsm #leusm #oncology onclive.com/view/fda-requi…

R. Lor Randall, MD, FACS, discusses the changing field of orthopedic oncology and gives his takeaways from the American Academy of Orthopedic Surgeons Meeting. R. Lor Randall UC Davis Comprehensive Cancer Cent #oncology onclive.com/view/as-orthop…

A functional precision medicine approach combining genomic testing with drug sensitivity testing was feasible for informing treatment decisions for pediatric patients with R/R solid and hematologic malignancies. Nature Medicine #oncology #pediatriccancer onclive.com/view/functiona…

The FDA has approved alectinib as adjuvant treatment in select patients with ALK-positive non–small cell lung cancer. U.S. FDA #lcsm #oncology onclive.com/view/fda-appro…

Pembrolizumab in combination with TheraSphere™ Yttrium-90 radioembolization represents a potential combination treatment avenue for patients with poor-prognosis, advanced HCC. IU School of Medicine #hcc #oncology onclive.com/view/y-90-radi…

Idalid Franco, MD, MPH, discusses the integration of immunotherapy, molecular biomarkers, and risk factors for recurrence into the endometrial cancer paradigm. Idalid "Ivy" Franco MD MPH Brigham and Women's Hospital @AcroRadOnc #gyncsm #ACRO2024 #radonc onclive.com/view/navigatin…

Adding tivumecirnon to pembrolizumab elicited responses and was well tolerated in patients with recurrent or metastatic HNSCC who were previously exposed to a checkpoint inhibitor, particularly those with HPV–positive disease. Duke Cancer #hnscc #oncology onclive.com/view/tivumecir…

Vikram Narayan, MD, details the mechanism of action of the nadofaragene firadenovec and how the agent is impacting care for patients with BCG-unresponsive non–muscle invasive bladder cancer. Vikram M. Narayan, MD Winship Cancer Institute of Emory University #blcsm onclive.com/view/narayan-d…

High therapy adherence rates were observed in patients with CLL who initiated therapy through an integrated health-system specialty pharmacy. Vanderbilt Specialty Pharmacy @vumchealth #leusm #lymsm onclive.com/view/cll-sll-t…

ICYMI: Pirtobrutinib demonstrated promising efficacy and a tolerable safety profile in heavily pretreated patients with R/R mantle cell lymphoma who received prior therapy w/ a covalent BTK inhibitor. Jonathon Cohen MD MS Winship Cancer Institute of Emory University #oncology #hematology onclive.com/view/pirtobrut…

In this #OncLiveOnAir episode, Drs Goyal, Bishop, Kelley, and Kuhlman discuss ways to prepare pts w/ cholangiocarcinoma for FGFR inhibitor–related AEs. #oncology onclive.com/view/expert-an…

Join our upcoming webinar “Optimizing Treatment Outcomes in Advanced NSCLC With Concurrent Biomarker Testing”. Discover key practice gaps impacting biomarker testing and targeted therapy utilization in advanced NSCLC. bit.ly/3TWXknG

Eftilagimod Alpha Plus Pembrolizumab Elicits Early Efficacy Signals in Metastatic HNSCC #hncsm #oncology onclive.com/view/eftilagim…

OBX-115 engineered tumor-infiltrating lymphocyte cell therapy shows durable antitumor responses in patients with immune checkpoint inhibitor-resistant advanced #melanoma , according to a study led by our Dr. Rodabe Amaria. brnw.ch/21wJ96z OncLive.com #AACR24 #EndCancer